Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fecal flora in preparing micro-ecological preparation for treating chronic hepatitis B

A technology of chronic hepatitis B and fecal flora, applied in the fields of application, antiviral agents, allergic diseases, etc., to achieve the effect of promoting the reduction of HBsAg titer

Inactive Publication Date: 2020-01-10
XIAMEN UNIV
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the use of flora transplantation or other probiotics to treat HBeAg-negative chronic hepatitis B patients in the field of basic research at home and abroad. If the HBsAg titer of these patients can be reduced through clinical treatment, the HBsAg titer can be controlled at a relatively low Low level or even achieve HBsAg clearance in patients will have strong clinical significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fecal flora in preparing micro-ecological preparation for treating chronic hepatitis B

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0042] The preparation method of the flora capsule can be: pack the flora liquid obtained in step 1) with a capsule material, pack it and store it at -80°C to form a flora capsule; the capsule material It is the way of adopting double-layer suit.

[0043] The feces flora can be used in the preparation of medicines for treating HBeAg-negative chronic hepatitis B. It can be used in combination with other antiviral drugs such as entecavir, as long as they do not produce other adverse effects, such as allergic reactions.

[0044] The feces flora can be used in the preparation of medicines for alleviating the disease response of patients with chronic hepatitis B. The remission is not limited to changes in indicators such as ALT, AST, and HBsAg.

[0045] The feces flora can be used in the preparation of medicines for reducing HBsAg content in patients with chronic hepatitis B.

[0046] The feces flora can be used in the preparation of medicines for regulating the immune function ...

Embodiment 1

[0052] Example 1: Isolation and extraction of fecal flora from healthy donors

[0053] Strictly follow the inclusion and exclusion criteria of healthy donors to select suitable donors. Dissolve 100-200 g of the collected donor feces in 750-1000 mL of 0.9% NaCl solution, and remove the residue through the feces analysis pretreatment instrument TG-01 produced by Xiamen Chengge Biotechnology Co., Ltd. and supporting consumables to obtain fecal bacteria 30 ~40g, and prepared into oral flora capsules.

Embodiment 2

[0054] Embodiment 2: Patient's grouping and clinical application

[0055] 1. Inclusion criteria of patients

[0056] 1. Age 18-65 years old;

[0057] 2. No drinking history or equivalent alcohol consumption <140g per week for men and <70g per week for women;

[0058] 3. Meet the diagnostic criteria for HBeAg-negative chronic hepatitis B in the guidelines for the prevention and treatment of chronic hepatitis B in my country;

[0059] 4. Conform to the indications for antiviral drug treatment in the guidelines for the prevention and treatment of chronic hepatitis B in my country;

[0060] 5. HBsAg positive after standard antiviral drug treatment for more than 1 year;

[0061] 6. Serum transaminase and glutamyl aminotransferase are within the upper limit of the normal value, or the increase is less than 10 times the normal value;

[0062] 7. Those who voluntarily participate in this research and sign the informed consent form.

[0063] Note: Patients who meet the above 7 ite...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a fecal flora in preparing a micro-ecological preparation for treating chronic hepatitis B and relates to the technical field of intestinal micro-ecology. A transplanting method of the fecal flora comprises the following steps of 1) separating and purifying the fecal flora in healthy donor feces; and 2) transplanting the fecal flora into an intestinal tract of a patient, and remodeling the unbalanced intestinal flora of the patient to a balanced state. The fecal flora can be applied to preparing a drug for treating HBeAg negative chronic hepatitis B, canbe used by combining with other antiviral drugs, such as entecavir, as long as no other adverse effect, such as anaphylaxis, is generated and can be applied to preparing a drug for relieving disease response of a patient with the chronic hepatitis B, a drug for lowering the HBsAg content of the patient with the chronic hepatitis B, a drug for regulating the immune function of the patient with thechronic hepatitis B and a health care product, a beverage, a enteral nutrition preparation or a dietary supplement for relieving or adjunctively treating the chronic hepatitis B.

Description

technical field [0001] The invention relates to the technical field of intestinal microecology, in particular to the application of fecal flora and its transplantation method in the preparation of microecological preparations for treating HBeAg-negative chronic hepatitis B. Background technique [0002] Chronic Hepatitis B (CHB) is a globally prevalent HBV-infected disease. It is estimated that there are about 2 billion HBV-infected people in the world, and 250 million chronic hepatitis B-infected people. If not effectively treated, they may develop liver cancer , liver cirrhosis and other end-stage liver diseases and lead to death. The burden of chronic hepatitis B disease in my country is relatively serious. It is estimated that there are more than 70 million hepatitis B virus carriers and about 28 million chronic hepatitis B patients. The number of deaths due to hepatitis B accounts for nearly 50% of the world. The current hepatitis B treatment drugs mainly include inter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/741A61P31/20A61P1/16A61P37/02A23L33/135A61K31/522
CPCA23L33/135A23V2002/00A61K31/522A61K35/741A61P1/16A61P31/20A61P37/02A61K2300/00A23V2200/30A23V2200/3204Y02A50/30
Inventor 任建林陈章然谢予柔许鸿志吴景烔周飞
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com